A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants (529 DDI ITZ)
A Phase 1 Open-label Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Icalcaprant in Healthy Adult Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: ABBVIE CALL CENTER
- Phone Number: 844-663-3742
- Email: abbvieclinicaltrials@abbvie.com
Study Locations
-
-
Illinois
-
Grayslake, Illinois, United States, 60030
- Acpru /Id# 271617
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Body Mass Index (BMI) is ≥ 18.0 to ≤ 32.0 kg/m^2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters.
- A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.
Exclusion Criteria:
- History of any clinically significant sensitivity or allergy to any medication or food.
- Exposure to icalcaprant within the past 90 days.
- History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption [e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome, gastric surgery (except pyloromyotomy for pyloric stenosis during infancy), cholecystectomy, vagotomy, bowel resection, etc.].
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Icalcaprant with Itraconazole
Participants will receive oral Icalcaprant with Itraconazole up to 8 days and then followed for 30 days.
|
Oral capsule
Other Names:
Oral capsule
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum Observed Plasma Concentration (Cmax) of Icalcaprant
Time Frame: Up to approximately 14 days
|
Cmax of Icalcaprant
|
Up to approximately 14 days
|
|
Time to Cmax (Tmax) of Icalcaprant
Time Frame: Up to approximately 14 days
|
Tmax of Icalcaprant
|
Up to approximately 14 days
|
|
Terminal Phase Elimination Rate Constant (Beta) of Icalcaprant
Time Frame: Up to approximately 14 days
|
Beta of Icalcaprant
|
Up to approximately 14 days
|
|
Terminal Phase Elimination Half-Life (t1/2) of Icalcaprant
Time Frame: Up to approximately 14 days
|
T1/2 of Icalcaprant
|
Up to approximately 14 days
|
|
Area under the plasma concentration-time curve (AUC) of Icalcaprant
Time Frame: Up to approximately 14 days
|
AUC of Icalcaprant
|
Up to approximately 14 days
|
|
Area under the plasma concentration-time curve from time 0 until the last measurable Concentration (AUCt) of Icalcaprant
Time Frame: Up to approximately 14 days
|
AUCt of Icalcaprant
|
Up to approximately 14 days
|
|
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of Icalcaprant
Time Frame: Up to approximately 14 days
|
AUCinf of Icalcaprant
|
Up to approximately 14 days
|
|
Number of Participants with Adverse Events (AEs)
Time Frame: Up to approximately 47 days
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
The investigator assesses the relationship of each event to the use of study
|
Up to approximately 47 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: ABBVIE INC., AbbVie
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Anti-Infective Agents
- Antifungal Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Enzyme Inhibitors
- Steroid Synthesis Inhibitors
- Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- 14-alpha Demethylase Inhibitors
- Itraconazole
Other Study ID Numbers
Other Study ID Numbers
- M25-529
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.